LONDON, Sept. 12, 2017 /PRNewswire/ -- The Global Diagnostic Imaging Partnering Terms and Agreements 2010 to 2017 report provides comprehensive understanding and unprecedented access to the diagnostic imaging partnering agreements entered into by the worlds leading healthcare companies.
The report provides a detailed understanding and analysis of how and why companies enter diagnostic imaging partnering deals. This report provides details of the latest diagnostics agreements announced in the healthcare sectors, covering:
Imaging
CT
Endoscope
Molecular and nuclear
PET
SPECT
MRI
Ultrasound
X ray
Angiography
Fluoroscopy
Mammography
This report provides an overview of diagnostic imaging dealmaking, the common clauses, rights and options in the partnering agreement, and also a comprehensive review of deals signed in since 2010.
This report provides a comprehensive and detailed review of all diagnostic imaging deals announced since 2010. The comprehensive agreements chapter is organized by company A-Z, stage of development at signing, deal type, and therapy focus. Each deal title links via Weblink to an online version of the actual deal at Current Agreements (www.currentagreements.com) deals and alliances database, providing easy access to each deal on demand. Where available, the full deal contract document is also provided and indicated by a document symbol.
Contract documents provide unsurpassed access to the detail of a deal normally announced in brief summary through a press release. Detailed analysis of a contract allow better understanding of the terms agreed between the parties, and importantly the basis under which monies and licensing rights are exchanged.
The initial chapters of this report provide an orientation of Diagnostic Imaging dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Diagnostic Imaging dealmaking since 2010, including details of average headline, upfront, milestone and royalty terms.
Chapter 3 provides a review of the leading Diagnostic Imaging deals since 2010. Deals are listed by headline value, signed by big pharma, most active Diagnostic Imaging dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive listing of the top 25 most active companies in Diagnostic Imaging dealmaking with a brief summary followed by a comprehensive listing of Diagnostic Imaging deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
